The U.S. District Court for the District of New Jersey has granted AstraZeneca Pharmaceuticals' motion for a temporary restraining order (TRO) halting sales of Teva's generic Pulmicort Respules (budesonide inhaled solution). In conjunction with the order against Teva, AZ will also stop all sales of its authorized generic budesonide inhalation suspension product and take the necessary steps to comply with the Court's decision. Par Pharmaceutical is the licensed distributor for AZ's generic version of Pulmicort Respules.
   
The TRO remains in effect until further notice by the Court. This action does not impact sales of branded Pulmicort Respules.

News from our sister sites